Diabetes mellitus and hypothyroidism: Strange bedfellows or mutual companions?

Barry I Joffe, Larry A Distiller

Abstract
Clinicians should be cognizant of the close relationship that exists between two of the most common endocrine disorders, primary hypothyroidism and diabetes mellitus. This applies to both type 1 and type 2 diabetes. However, the association is greater in type 1 diabetes, probably due to shared autoimmune predisposition. In type 2 diabetes, the connection is more complex. Biochemical screening for thyroid dysfunction in patients with diabetes is advised.

Core tip: Clinicians should be cognisant of the close relationship that exists between two of the commonest endocrine disorders, primary hypothyroidism and diabetes mellitus. This applies to both type 1 and type 2 diabetes. However, the association is greater in type 1 diabetes, probably due to shared autoimmune predisposition. In type 2 diabetes, the connection is more complex. Biochemical screening for thyroid dysfunction in patients with diabetes is advised.

INTRODUCTION
Two of the main clinical disorders encountered in endocrine clinics are diabetes mellitus and primary hypothyroidism. Diabetes can be divided into type 1 diabetes mellitus (T1DM) and type 2 diabetes mellitus (T2DM) respectively. However, the association is greater in T1DM, probably because of the shared autoimmune predisposition. In patients with T2DM, the relationship is somewhat weaker and the explanation less clear-cut. Factors such as dietary iodine deficiency, metformin-induced thyroid stimulating hormone suppression and poor glycaemic control may all be implicated. Further translational research is required for greater clarification. Biochemical screening for abnormal thyroid function in individuals who have diabetes is warranted, particularly in females with T1DM, and therapy with L-thyroxine appropriately instituted if hypothyroidism is confirmed.

© 2014 Baishideng Publishing Group Inc. All rights reserved.

Key words: Type 1 diabetes; Type 2 diabetes; Primary hypothyroidism; Autoimmune disorders; Thyroid screening; Thyroid treatment
thyroidism in T1DM and T2DM were also assessed.

### TYPE 1 DIABETES AND HYPOTHYROIDISM

Autoimmune thyroid disease is the commonest autoimmune disorder associated with T1DM\[^5\]. This should not be surprising as T1DM and autoimmune thyroid disease share an autoimmune disposition, and recent studies have shown a shared genetic susceptibility to both conditions\[^12\]. Regarding the shared genes involved in this immune predisposition, the CTLA-4, HLA class 11 and FOXP3 genes have been implicated. Like T1DM, autoimmune thyroid disease is due to organ-specific autoimmunity. There is infiltration of the thyroid gland with T-lymphocytes and the formation of autoreactive antibodies, particularly against thyroglobulin and thyroid peroxidase (TPOAb). These antibodies are commonly found in patients with T1DM and may be present in up to 25% of patients with T1DM at the time of diagnosis of the diabetes\[^8\]. The presence of thyroid antibodies is predictive of the later development of autoimmune thyroid dysfunction, usually hypothyroidism but also, less commonly, hyperthyroidism\[^3\]. Umpierrez et al\[^18\] reported that in patients with type 1 diabetes who had been followed for 18 years, those who were TPOAb-positive were much more likely to become hypothyroid than patients who showed negative antibodies at the outset.

Should hypothyroidism occur, even in a subclinical form, it may be associated with increased risk of hypoglycemia, by reduced hepatic glucose output and especially from impaired gluconeogenesis\[^11\]. There may also be reduced linear growth in children and adolescents\[^13\].

The prevalence of hypothyroidism in patients with T1DM has been estimated to be between 17% and 30%\[^5\]. In our recently published survey of T1DM at a private diabetes clinic in Johannesburg, South Africa\[^15\], we found a 20.2% prevalence of hypothyroidism in 504 patients with established T1DM. Females showed a significantly higher prevalence than did males (30.9% vs 10.1%, \(P < 0.001\)) (Table 1). Our prevalence rate was slightly higher than that in a study by González et al\[^14\], which involved smaller patient numbers. That report again emphasized that the presence of thyroperoxidase autoantibodies at T1DM onset was highly predictive for the development of subsequent thyroid dysfunction. In our survey, we also noted an increased prevalence of other organ specific autoimmune diseases such as Addison's disease, celiac disease and pernicious anemia, but at a much lower frequency.

### TYPE 2 DIABETES AND HYPOTHYROIDISM

In T2DM, the association with hypothyroidism is more complex. It is unlikely to be a coincidence of two common endocrine disorders, since the prevalence of hypothyroidism is higher than in the general population. This has been demonstrated in a number of epidemiological studies including our own\[^15-18\], with the prevalence of hypothyroidism varying between 11% and over 30% across different ethnic groups, as opposed to 4% reported in the general population\[^16-19\]. The presence of undiagnosed hypothyroidism may increase cardiovascular risk by aggravating dyslipidemia, insulin resistance, obesity and vascular endothelial dysfunction\[^20,21\]. Factors that could be implicated in this association are rather ill defined and may be complex. Insufficient iodine intake in the diet is one possibility, since a recent study highlighted reduced iodine consumption in 3 major American weight reducing programmes\[^22\]. A report documenting a TSH-lowering effect of metformin in T2DM\[^23\] may also be relevant, although the relationship between metformin and hypothyroidism is likely to be a complex one. Our study suggested that metformin usage might actually be protective against hypothyroidism in patients with T2DM or perhaps that suppressed thyroid-stimulating hormone caused by metformin may lead to physicians missing the diagnosis when thyroid-stimulating hormone measurement is the only screening method employed\[^16\]. Additionally, poorly-controlled diabetes may induce alterations in thyroid function tests similar to that occurring in systemic illnesses i.e. lower levels of all thyroid hormone measurements\[^24\]. Finally the possibility of alterations in the gut microflora being detected in both T2DM and thyroid dysfunction warrants attention. Further studies are clearly required to clarify the causal relationships between these two major endocrine disorders.

### COMPARATIVE FREQUENCIES OF HYPOTHYROIDISM IN TYPE 1 AND TYPE 2 DIABETES

From our own large database of patients with diabetes in Johannesburg, we were able to establish that the overall frequency of diagnosed hypothyroidism in T1DM was almost double that seen in T2DM (Table 2). This applied to both female and male subjects. The closer association of hypothyroidism with T1DM probably reflects their genetic predisposition. Hypothyroidism is higher than in the general population. This is predictive of the later development of autoimmune thyroid disease, especially if the patient is female. Insufficient iodine intake in the diet is one possibility, since a recent study highlighted reduced iodine consumption in 3 major American weight reducing programmes. A report documenting a TSH-lowering effect of metformin in T2DM may also be relevant, although the relationship between metformin and hypothyroidism is likely to be a complex one. Our study suggested that metformin usage might actually be protective against hypothyroidism in patients with T2DM or perhaps that suppressed thyroid-stimulating hormone caused by metformin may lead to physicians missing the diagnosis when thyroid-stimulating hormone measurement is the only screening method employed. Additionally, poorly-controlled diabetes may induce alterations in thyroid function tests similar to that occurring in systemic illnesses i.e. lower levels of all thyroid hormone measurements. Finally the possibility of alterations in the gut microflora being detected in both T2DM and thyroid dysfunction warrants attention. Further studies are clearly required to clarify the causal relationships between these two major endocrine disorders.

#### Table 1  Prevalence of hypothyroidism in patients with type 1 diabetes n (%)

| Gender | Number of subjects | Prevalence of hypothyroidism |
|--------|-------------------|-----------------------------|
| Female | 246               | 76 (30.9) \(^a\)            |
| Male   | 258               | 26 (10.1)                   |
| Total  | 504               | 102 (20.2)                  |

\(^a\) \(P < 0.001\) vs males.
Table 2: Comparative prevalence of hypothyroidism in patients with type 1 and type 2 diabetes \( n \) (%)

| Diabetic subgroup | Number of subjects | Prevalence of hypothyroidism |
|-------------------|--------------------|-----------------------------|
| Type 1            | 504                | 102 (20.2%) \(^*\)         |
| Type 2            | 918                | 108 (11.8%)                 |

\(^*\)P < 0.001 vs type 2 diabetes.

**RECOMMENDATIONS FOR THYROID SCREENING AND THERAPY**

Hypothyroidism can be clinically silent or aspects of poor diabetes metabolic control may mask its clinical features. In view of the extremely high prevalence of hypothyroidism in those with T1DM, screening for thyroid disease should be done in a systematic fashion. Regular screening will unmask a substantial number of individuals with asymptomatic thyroid dysfunction. Current guidelines advise screening type 1 diabetic subjects at the time of diagnosis or initial contact.\(^{10,27}\)

Thereafter, it is recommended that the TSH is measured annually or two-yearly, but more frequently in antibody-positive patients or individuals who develop a goiter.\(^{28}\) In the event of pregnancy, this becomes a necessity to prevent damage to fetal mental development secondary to undiagnosed maternal hypothyroidism.\(^{29}\)

For patients with T2DM, the recommendations for biochemical screening are less obvious and depend on factors such as sex, ethnic origin and age. Advice regarding routine testing is either vague\(^{27}\) or firmly against routine yearly screening of type 2 diabetic patients.\(^{28}\) Gopinath \textit{et al.}\(^{28}\) reported no difference in the 5-year incidence of thyroid dysfunction in elderly patients with and without diabetes and another study by Chubb \textit{et al.}\(^{31}\) also reported no development of frank hypothyroidism in female type 2 diabetes who manifested subclinical disease. This is in contrast to the data presented in this review, which highlights the increased prevalence of hypothyroidism in patients with T2DM. Selective periodic testing of patients with T2DM is probably warranted. Thyroid antibodies and serum thyroid stimulating hormone (TSH) levels are a useful means of identifying patients with diabetes who are at the greatest risk of thyroid dysfunction. Serum TSH concentrations in the upper range of normal appear to predict the development of future hypothyroidism. In one study involving subjects with both T1DM and T2DM, a TSH concentration above 1.53 mU/L predicted later hypothyroidism.\(^{15}\) Therefore those with TSH concentrations in the upper normal range probably warrant more frequent, perhaps annual, re-testing. Regarding therapy in patients with diabetes, L-thyroxine should be instituted after confirmed biochemical diagnosis. Since patients with T2DM frequently have underlying ischemic heart disease, therapy in these patients should be started at low dosage (\textit{e.g.}, 25 μg daily). This should be gradually increased over time, using the serum TSH level as a marker of adequate replacement. A serum TSH between 0.5 and 2.0 mU/L is generally considered the optimal target range to aim for.\(^{30}\)

**CONCLUSION**

Diabetes and hypothyroidism are indeed mutual companions based on the clinical studies that we have reviewed. This applies both to patients with T1DM and T2DM, although patients with T1DM are most predisposed. However, in both subtypes of diabetes, females are more vulnerable to develop hypothyroidism. Clinicians should be alerted to the close relationship that exists between these two common endocrine disorders and the importance of biochemical screening for hypothyroidism as indicated above. Appropriate thyroid replacement therapy can be introduced at an early opportunity, when required.

**ACKNOWLEDGMENTS**

We would like to thank Arlene Fine for her expert secretarial assistance; Michael Brown for his invaluable assistance in editing this manuscript.

**REFERENCES**

1. Groop L. Genetic and metabolic heterogeneity of diabetes. \textit{Int Diabetes Monitor} 2000; 12: 1-6. Available from: URL: http://www.internationaldiabetesmonitor.com/PDFSs/212.pdf
2. DeFronzo RA. Pathogenesis of type 2 diabetes mellitus. \textit{Med Clin North Am} 2004; 88: 787-835; ix [PMID: 15308580]
3. Hollowell JG, Staehling NW, Flanders WD, Hannon WH, Gunter EW, Spencer CA, Braverman LE. Serum TSH, T(4), and thyroid antibodies in the United States population (1988 to 1994): National Health and Nutrition Examination Survey (NHANES III). \textit{J Clin Endocrinol Metab} 2002; 87: 489-499 [PMID: 11836274]
4. Diez JJ, Iglesias P. An analysis of the relative risk for hypothyroidism in patients with Type 2 diabetes. \textit{Diabet Med} 2012; 29: 1510-1514 [PMID: 22507220]
5. Roldán MB, Alonso M, Barrio R. Thyroid autoimmunity in children and adolescents with Type 1 diabetes mellitus. \textit{Diabetes Nutr Metab} 1999; 12: 27-31 [PMID: 10517303]
6. Huber A, Menconi F, Corathers S, Jacobson EM, Torer Y. Joint genetic susceptibility to type 1 diabetes and autoimmune thyroiditis: from epidemiology to mechanisms. \textit{Endocr Rev} 2008; 29: 697-725 [PMID: 18776148]
7. Villano MJ, Huber AK, Greenberg DA, Golden BK, Concepcion E, Torer Y. Autoimmune thyroiditis and diabetes: dissecting the joint genetic susceptibility in a large cohort of multiplex families. \textit{J Clin Endocrinol Metab} 2009; 94: 1458-1466 [PMID: 19141582]
8. Triolo TM, Armstrong TK, McFann K, Yu L, Reeves MJ, Klingensmith GJ, Eisenbarth GS, Barker JM. Additional autoimmune disease found in 33% of patients at type 1 diabetes onset. \textit{Diabetes Care} 2011; 34: 1211-1213 [PMID: 21430083]
9. Kordonouri O, Deiss D, Danne T, Dorow A, Bassir C, Gruters-Kieslich A. Predictivity of thyroid autoantibodies for the development of thyroid disorders in children and adolescents with Type 1 diabetes. \textit{Diabet Med} 2002; 19: 518-521 [PMID: 12006066]
10. Umpierrez GE, Latif KA, Murphy MB, Lambeth HC, Stentz F, Bush A, Kitabchi AE. Thyroid dysfunction in patients with type 1 diabetes: a longitudinal study. \textit{Diabetes Care} 2003; 26: 1181-1185 [PMID: 12663594]
Joffe BI et al. Diabetes and hypothyroidism

11 Mohn A, Di Michele S, Di Luzio R, Tuminí S, Chiarelli F. The effect of subclinical hypothyroidism on metabolic control in children and adolescents with Type 1 diabetes mellitus. Diabete Metab 2002; 19: 70-73 [PMID: 11869306]

12 Chase HP, Garg SK, Cockerton RS, Wilcox WD, Walatraens PA. Thyroid hormone replacement and growth of children with subclinical hypothyroidism and diabetes. Diabet Med 1990; 7: 299-303 [PMID: 2140081]

13 Joffe BI, Distiller L, Landau S, Blacking L, Klishieffitz A. Spectrum of autoimmune disorders in type 1 diabetes-a cross sectional audit. J Diabetes Metabolism 2010; 1: 112 [DOI: 10.4172/2155-6156.1000112]

14 Gonzalez GC, Caneel J, Rodriguez-Espinosa J, Mauricio D, de Leiva A, Perez A. Thyroid autoimmunity at onset of type 1 diabetes as a predictor of thyroid dysfunction. Diabetes Care 2007; 30: 1611-1612 [PMID: 17372152 DOI: 10.2337/dc07-1504]

15 Kadiyala R, Peter R, Okosime OE. Thyroid dysfunction in patients with diabetes: clinical implications and screening strategies. Int J Clin Pract 2010; 64: 1130-1139 [PMID: 20642711 DOI: 10.1111/j.1742-1241.2010.02376.x]

16 Distiller LA, Polakow ES, Joffe BI. Type 2 diabetes mellitus and hypothyroidism: the possible influence of metformin therapy. Diabet Med 2014; 31: 172-175 [PMID: 24151823 DOI: 10.1111/dme.12342]

17 Demitrost L, Ranarib S. Thyroid dysfunction in type 2 diabetes mellitus: A retrospective study. Indian J Endocrinol Metab 2012; 16: S334-S335 [PMID: 23565418]

18 Ghazali SM, Abbiyezua FM. Thyroid dysfunction in type 2 diabetes seen at the University College Hospital, Ibadan, Nigeria. Niger J Physiol Sci 2010; 25: 173-179 [PMID: 22314957]

19 Olsen AH, Kelsberg G, Coffey J, Hsu JT. Clinical inquiries. Should we screen women for hypothyroidism? J Fam Pract 2004; 53: 653-655 [PMID: 15298841]

20 Brenta G. Diabetes and thyroid disorders. Br J Diabetes Vasc Dis 2010; 10: 172-177 [DOI: 10.11177/1474651410571321]

21 Duntas LH, Orgiiazi J, Brabant G. The interface between thyroid and diabetes mellitus. Clin Endocrinol (Oxf) 2011; 75: 1-9 [PMID: 21521298]

22 Kurit M, Pearce EN, Braverman LE, He X, Leun AM. Iodine contents of US Weight Loss Food. The Endocrine Society’s 95th Annual Meeting and Expo, June 15-18. San Francisco, 2013. Available from: URL: http://press.endocrine.org/doi/abs/10.1210/endo-meetings.2013.THPTA.4.MON-457

23 Cappelli C, Rotondi M, Pirola I, Agosti B, Gandossi E, Valentini U, De Martino E, Cimino A, Chiovato L, Agabiti-Rosei E, Castellano M. TSH-lowering effect of metformin in type 2 diabetic patients: differences between euthyroid, untreated hypothyroid, and euthyroid on L-T4 therapy patients. Diabetes Care 2009; 32: 1589-1590 [PMID: 19502536]

24 Wartofsky L, Burton KD. Alterations in thyroid function in patients with systemic illness: the “euthyroid sick syndrome”. Endocr Rev 1982; 3: 164-217 [PMID: 6806805]

25 Wu P. Thyroid disease and diabetes. Clin Diabetes 2000; 18: 1-4. Available from: URL: http://journal.diabetes.org/cpindiabetes/v18n12000/pg38.htm

26 Kordonouri O, Maguire AM, Knip M, Schober E, Lorini R, Holl RW, Donaghue KC. Other complications and associated conditions with diabetes in children and adolescents. Pediatr Diabetes 2010; 10 Suppl 12: 204-210 [PMID: 19756431]

27 American Diabetes Association. Standards of medical care in diabetes—2014. Diabetes Care 2014; 37 Suppl 1: S14-S80 [PMID: 24357209]

28 British Thyroid Association and Association of Clinical Biochemistry Guidelines, 2006. Available from: URL: http://www.british-thyroid-association.org/info-for-patients/Docs/TFT_guideline_final_version_July_2006.pdf

29 Maps E. Better thyroid management during pregnancy. Endocrine News 2013; 16-19. Available from: URL: http://www.endocrine.org/~/media/endosociety/Files/Publications/Endocrine%20News/Issues/2013/EndocrineNews-February2013.pdf

30 Gopinath B, Wang JJ, Killey A, Wall JR, Leeder SR, Mitchell P. Type 2 diabetes does not predict incident thyroid dysfunction in the elderly. Diabetes Res Clin Pract 2008; 82: e11-13 [PMID: 18838187]

31 Chubb SA, Davis WA, Inman Z, Davis TM. Prevalence and progression of subclinical hypothyroidism in women with type 2 diabetes: the Fremantle Diabetes Study. Clin Endocrinol (Oxf) 2005; 62: 480-486 [PMID: 15807880]

32 Warren RE, Perros P, Nyirenda MJ, Frier BM. Serum thyrotropin is a better predictor of future thyroid dysfunction than thyroid autoantibody status in biochemically euthyroid patients with diabetes: implications for screening. Thyroid 2004; 14: 853-857 [PMID: 15988383]

33 Demers LM, Spencer CA. Laboratory Medicine Practise Guidelines: Laboratory support for the diagnosis and monitoring of thyroid disease. National Academy of Clinical Biochemistry, 2002. Available from: URL: http://www.aacc.org/~media/practice-guidelines/thyroid-disease/thyroidarchived2010.pdf?la=en
